Reply to "Metronomic chemotherapy beyond misconceptions" - Haematologica 2013;98(11):e145

Metronomic chemotherapy beyond misconceptions.

Antiangiogenic metronomic chemotherapy.

Accessible online at: www.karger.com/onk Fax +49 761 4 52 07 14 E-mail [email protected] www.karger.com Most of the phase I–II clinical studies performed up to now used ‘metronomic-like’ schedules of cytostatic agents, often administered using weekly schedules of vinca alkaloids, taxanes, anthracyclines or alkylating agents resulting, however, in high dose-density treatments. A rational ide...

Metronomic Chemotherapy Roberta

Accessible online at: www.karger.com/onk Fax +49 761 4 52 07 14 E-mail [email protected] www.karger.com Most of the phase I–II clinical studies performed up to now used ‘metronomic-like’ schedules of cytostatic agents, often administered using weekly schedules of vinca alkaloids, taxanes, anthracyclines or alkylating agents resulting, however, in high dose-density treatments. A rational ide...

Moving beyond misconceptions to a diagnosis

French neurologist Georges Gilles de la Tourette first described the condition that bears his name, a name familiar to the lay public and health professionals alike. Once considered so rare that neurologists might expect to witness the disorder perhaps once in their professional lifetime, Tourette syndrome (TS) is, in fact, common enough that virtually all pediatricians will have several patien...

Metronomic chemotherapy against cancer: from paradigm to clinical practice?

We describe two paradigmatic cases where metronomic antitumor chemotherapy was successfully employed in patients not suitable for standard treatments. The first patient was affected by advanced soft tissue sarcoma but she also had ischemic cardiopathy. She received oral cyclophosphamide 50 mg once daily and methotrexate 2.5 mg bid twice weekly, obtaining a significant clinical response with a p...